produção científica

Artigos recentes em revistas Indexadas

1. Bisphosphonates in multiple myeloma
Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Cochrane Database Syst Rev. 2010 Mar 17;3:CD003188.

2. Epidemiologic characteristics of renal cell carcinoma in Brazil
Nardi AC, Zequi C, Clark OA, Almeida JC, Glina S. Int Braz J Urol. 2010 Mar-Apr; 36(2): 151-7.

3. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
Supportive Care in Cancer, PMID: 20495832 - 2010.

4. A exposição ocupacional ao chumbo e os riscos à saúde do trabalhado
Jornal Brasileiro de Economia da Saúde, v. 2, p. 8-14, 2010.

5. Risco ambiental nas grandes metrópoles brasileiras. Jornal Brasileiro de Economia da Saúde
v. 2, p. 22-28, 2010.

6. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
Cochrane Database Syst Rev. 2007 Jan 24; (1):CD005413.

7. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis
Int J Radiat Oncol Biol Phys. 2006 Mar 1; 64(3):784-91.

8. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trial
J Clin Oncol. 2005 Jun 20; 23 (18):4198-214.

9. Divulgação científica e senso crítico: manual do jornalista científic
Revista Multiciência. 2005 Mai (4).

10. Colony stimulating factors for chemotherapy induced febrile neutropenia
Cochrane Database Syst Rev. 2003;(3):CD003039.

11. Allogeneic peripheral blood stem cell versus bone marrow for the treatment of hematological malignancies – a meta-analysis. Blood 2001; 98(11)414a.

12. Is clinical research still too haphazard?
Lancet 2001 Nov 10;358(9293):1648.

13. Antibiotic prophylaxis for transrectal prostate biopsy
Cochrane Database Syst Rev. 2011 May 11;5:CD006576.

14. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis
Lung Cancer. 2011 Mar 4. PMID: 21377753 .


Capítulos de livros e outras publicações

1. Direito à Vida e à Saúde: Impactos Orçamentário e Judicial. Ana Carla Bliacheriene, José S Santos, Denizar Vianna, Otavio Clark, et. al. Editora Atlas. Agosto 2010.

2. Tratamento da dor oncológica: evidências para a prática clínica. Clark O, Paladini L, Clark L, Engel T, Pegoreti B, Faleiros E. Revista Dor e Analgesia. Ano II, (12) Agosto 2009, p.10.

3. Agentes estimuladores da eritropoiese para a anemia relacionada ao câncer e ao seu tratamento. Paladini L, Clark O, Clark L, Engel T, Pegoreti B, Faleiros E. Revista Prática Hospitalar Ano XI (63), p.76. Junho 2009.

4. Série de fascículos (6) sobre Medicina Baseada em Evidências. Produzidos pela Triunfo Marketing. Campinas 2008-2009.

5. ASCO 2007: um resumo crítico. Clark O, Clark L. Revista Visão Médica em Oncologia. Ano I, No. 3; p.38. 2007.

6. Urologia Baseada em Evidências: por que é importante? Clark L, Sasse A, Sasse E, Clark O. Cancer Urológico e suas interfaces. Ano I, No.I, p. 8-9. Junho 2005.

7. Importância das diretrizes baseadas em evidências. Clark L, Sasse A, Sasse E, Clark O. Urominas. Ano 9, p.11. Dezembro 2005.

8. Boas intenções nem sempre resultam em boas ações. Correio Popular de Campinas. Ed. 22/11/2004, p. 3.

9. Manual de Orientação: Câncer e quimioterapia. Informações úteis aos pacientes e seus familiares. Clark L, Martins LC, Fernandes QP, Bezerra TL. 2004.

10. Baustian GH, Clark LGO, Garg S. Breast Cancer. In: Steven Merahn. (Org.). PDXMD Hematology & Oncology. Philadelphia: Elsevier Science, 2003, v. , p. 74-117.

11. Groves MJ, Clark LGO, Chen NN. Carcinoid Syndrome. In: Steven Merahn. (Org.). PDXMD Hematology & Oncology. Philadelphia: Elsevier Science, 2003, v. , p. 120-148.

12. Jones RC, Clark LGO, Garg S. Multiple Myeloma. In: Steven Merahn. (Org.). PDXMD Hematology & Oncology. Philadelphia: Elsevier Science, 2003, v. , p. 530-579.

13. Baustian GH, Clark LGO, Castro JE. Osteosarcoma. In: Steven Merahn. (Org.). PDXMD Hematology & Oncology. Philadelphia: Elsevier Science, 2003, v. , p. 608-632.

14. Baustian GH, Clark LGO, Castro JE. Prolactinoma. In: Steven Merahn. (Org.). PDXMD Hematology & Oncology. Philadelphia: Elsevier Science, 2003, v. , p. 736-761

15. Uro-Oncologia Baseada em Evidências. Vol I - Próstata. Clark O, Clark L, Ferreira U, Denardi F, Rodrigues-Neto N. São Paulo: Sociedade Brasileira de Urologia-SP, 2001 (Brochura).

16. Uro-Oncologia Baseada em Evidências. Vol II Carcinoma renal. Clark O, Clark L, Sasse A, Ferreira U, Denardi F, Rodrigues-Neto N. São Paulo-SP: Sociedade Brasileira de Urologia-SP, 2001 (Brochura)




Apresentações em Congressos Médicos

1. Efficacy of adjuvant chemotherapy with gemcitabine (gem) compared to surgery-only in patients with resected pancreatic cancer: systematic review (sr) and meta-analysis (ma) In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010.

2. Efficacy and cardiac safety of trastuzumab (t) in the adjuvant treatment of her2-positive early-stage breast cancer: a systematic review (sr) and meta-analysis (ma). In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010.

3. Costs of supportive care (sc) for the treatment of myelodisplastic syndrome (mds) in brazil: an analysis from the private payer's perspective. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010.

4. Bevacizumab (bev) in metastatic breast cancer: a real world data analysis of the budgetary impact from the private sector's perspective in Brazil. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010

5. Current trends in health technology incorporation (hti) in brazil: inside the national health system's (nhs) black box. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010

6. Efficacy of the combination bevacizumab plus chemotherapy (bev-ct) compared to ct alone in previously untreated locally advanced or metastatic non-small cell lung cancer (nsclc): systematic review (sr) and meta-analysis (ma). Podium Presentation. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010.

7. Efficacy of palonosetron (pal) compared to other serotonin inhibitors (5-ht3r) in preventing chemotherapy induced nausea and vomiting (cinv) in patients receiving moderately or highly emetogenic (mohe) treatment: an update of the previously published systematic review and meta-analysis. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010

8. Interactive electronic interfaces (iei): bridging the communication gap by translating economic analysis results to decision makers everyday practice. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th European Meeting, 2010, Prague. Ispor Outcomes Research Digest, 2010

9. Retrospective Cost and Outcome Analysis of Breast Cancer Patients (BCP) Treated in a Brazilian Outpatient Cancer Center (OCC). In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting., 2010, Atlanta. Ispor Outcomes Research Digest, 2010.

10. Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine within the private market in Brazil. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting., 2010, Atlanta. Ispor Outcomes Research Digest, 2010.

11. Ideal Vial size for Bortezomib: Real World Data on Waste and Cost Reduction in Multiple Myeloma (MM). In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting., 2010, Atlanta. Ispor Outcomes Research Digest, 2010.

12. Intragastric baloon (IGB) for morbidily obese (MOP) and super obese patients (SOP): Systematic Review (SR) and Health Technology Assessment (HTA). In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting., 2010, Atlanta. Ispor Outcomes Research Digest, 2010.

13. Real world data on multiple myeloma (MM) treatment in Brazil: guidance for the private healthcare system (PHS). In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010, Atlanta. Ispor Outcomes Research Digest, 2010.

14. Real world data on multifraction (MFR) versus single fraction (SFR) radiotherapy to treat bone metastasis: impact im costs for private health care (PHC) providers in Brazil. In: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th European Conference., 2010, Atlanta. Ispor Outcomes Research Digest, 2010.

15. Auditoria Baseada em Evidências (ABE): impacto no custo do tratamento quimioterápico após 3 anos de implantação. Clark L, Alves A, Castro A, Clark O, Santos F. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2nd Latin America Conference. Rio de Janeiro, Setembro 2009. Prêmio de Melhor Apresentação de Podium.

16. Revisão de contas em oncologia e medicina baseada em evidências (MBE): impacto financeiro e busca pela qualidade. ISPOR 2nd Latin America Conference. Rio de Janeiro, Setembro 2009. Finalista.

17. Efficacy of palonosetron (pal) compared to other serotonin inhibitors (5-ht3r) in preventing chemotherapy induced nausea and vomiting (cinv) in patients receiving moderately or highly emetogenic (mohe) treatment: systematic review and meta-analysis. ISPOR 2nd Latin America Conference. Rio de Janeiro, Setembro 2009. Finalista.

18. Erythropoiesis Stimulating Agents (ESAs) for the treatment of chemotherapy induced anemia in patients with hemoglobin levels (Hb) <11g/dl. A systematic review and meta-analysis. ISPOR 2nd Latin America Conference. Rio de Janeiro, Setembro 2009. Finalista.

19. Análise farmacoeconômica de antieméticos em quimioterapia altamente / moderadamente emetogênica: a perspectiva da fonte pagadora. ISPOR 2nd Latin America Conference. Rio de Janeiro, Setembro 2009. Finalista.

20. Comparação de custos e tempo para progressão entre Pemetrexede (P) e Docetaxel (D) no tratamento de segunda linha do câncer de pulmão não pequenas células (nsclc): dados do mundo real. ISPOR 2nd Latin America Conference. Rio de Janeiro, Setembro 2009.

21. Evidence-Based Medicine (EBM) and the profile of appeals following auditing in chemotherapy treatments. ISPOR 12th Annual European Congress. Paris, Outubro de 2009.

22. Budgetary Impact of Oral Chemotherapy: Real-World Data Analysis from Payer’s Perspectives in Brazil. ISPOR 12th Annual European Congress. Paris, Outubro de 2009.

23. Two different doses of palonosetron (PAL) for prevention of chemotherapy induced vomiting (CIV) in patients receiving moderately or highly emetogenic (MOHE) treatment: systematic review (SR) and meta-analysis (MA). ISPOR 12th Annual European Congress. Paris, Outubro de 2009. Finalista na categoria poster.

24. Trastuzumab on adjuvant breast cancer treatment: evidence synthesis and health technology evaluation. ISPOR 12th Annual European Congress. Paris, Outubro de 2009.

25. Trastuzumabe para o tratamento adjuvante da neoplasia de mama: síntese das evidências e análise da tecnologia. I Simpósio Internacional de Farmacoeconomia no SUS. Avaliação Tecnológica em Saúde. Belo Horizonte. Maio 2009.

26. Erythropoiesis Stimulating Agents (ESA) for the Treatment of Chemotherapy Induced Anemia in Patients with Hemoglobin Levels (Hb) <11g/Dl- a Systematic Review and Meta-Analysis. American Society of Hematology Annual Meeting. San Francisco. 2008. Abstracts Blood Nov 2008; 112: 1305.

27. Kinase inhibitors versus biological agents and / or chemotherapy for the treatment of metastatic kidney cancer: a cost minimization analysis. 4th Annual Meeting of HTAi (Health Technology Assessment International). Barcelona, Junho de 2007.

28. Evidence-based medicine program for a health plan in Brazil: coverage criteria for new technology-based interventions - an update. XIII Cochrane Colloquium - Corroboree, 2005, Melbourne. Program and abstracts, 2005. p. 64.

29. Economic impact of an evidence based assessment of bone densitometry in a private health plan in Brazil. XIII Cochrane Colloquium - Corroboree, 2005, Melbourne. Program and abstracts, 2005. p. 87.

30. Evidence based audit in oncology: analyses of three health plans in Brazil. XIII Cochrane Colloquium - Corroboree, 2005, Melbourne. Program and abstracts, 2005. p. 163.

31. Economic Impact of an evidence based approach to tumor marker request in a health plan in Brazil. XIII Cochrane Colloquium - Corroboree, 2005, Melbourne. Program and abstracts, 2005. p. 163.

32. Goserelina contra leuprolide para o tratamento do câncer de próstata: revisão sistemática e metanálise. XIV Congresso Brasileiro de Cancerologia, 2005, Rio de Janeiro. Revista Oficial - Anais do XIV Congresso Brasileiro de Cancerologia, 2005. p. 60.

33. Temozolomida para o tratamento do glioma maligno: revisão sistemática. XIV Congresso Brasileiro de Cancerologia, 2005, Rio de Janeiro. Revista oficial - Anais do XIV Congresso Brasileiro de Cancerologia, 2005. p. 76.

34. Erythropoiesis stimulating factors (esas) for the treatment of chemotherapy induced anemia in patients with hb 11g/dl. A systematic review (sr) and meta-analysis (ma).Apresentador: Otávio Clark, Evidências. 8o. Congresso Htai – Rio de Janeiro, 2011.

35. Therapies for rare diseases (RD): challenges in adoption and access. Is there a role for evidence-based medicine? Vanessa Teich, MedInsight; Camila Pepe, MedInsight; Luciana Clark, Evidências; Carlos Ruchaud, Genzyme; Elisa Sobreira, Genzyme. 8o. Congresso Htai – Rio de Janeiro, 2011.

36. Geftinib (G) versus conventional chemotherapy (CT) for the 1st line treatment of advanced non small cell lung cancer (NSCLC) patients with epidermal growth factor receptors mutation (EGFRM): a systematic review (SR) and meta-analysis (MA). Luciano Paladini, Evidências; Otávio Clark, Evidências; Tobias Engel, Evidências; Luciana Clark, Evidências. 8o. Congresso Htai – Rio de Janeiro, 2011.

37. Platin compounds (PC) plus Taxanes (T) against T alone for the treatment of metastatic breast cancer (MBC): a systematic review (SR) and meta-analysis (MA). Luciana Clark, Evidências; Tobias Engel, Evidências; Otávio Clark, Evidências; Luciano Paladini, Evidências. 8o. Congresso Htai – Rio de Janeiro, 2011.

38. Colony stimulating factors (CSF) for the treatment of febrile neutropenia (FN) in cancer patients: a systematic review (SR) and meta-analysis (MA). Otávio Clark, Evidências; Camila Pepe, MedInsight; Benjamin Djulbegovic, University Of South Florida; Gary Lyman, Duke University; Luciano Paladini, Evidências; Tobias Engel, Evidências; Luciana Clark, Evidências.8o. Congresso Htai – Rio de Janeiro, 2011.

39. New agents (NA) for the treatment of metastatic renal cell carcinoma (RCC): a critic systematic review (SR) and meta-analysis (MA). Marcela Andrea Duran Haun, UNICAMP;Otávio Clark, Evidências; Luciano Paladini, Evidências; Vanessa Teich, MedInsight; Wagner Matheus, UNICAMP; Ubirajara Ferreira, UNICAMP. 8o. Congresso Htai – Rio de Janeiro, 2011.

40. Cost-effectiveness and budget impact analysis of Rivaroxaban in the prevention of thromboembolic events in patients performing hip and knee arthroplasty in comparison with Dabigatran under the Brazilian private health care system perspective.

41. Alexandre Schiola, Bayer; Alessandra Pimentel Silva, Bayer; Natalia Bolzachini Santoni, Bayer;Luciano Paladini, Evidências; Vanessa Teich, MedInsight; Camila Pepe, MedInsight; Monique Marinho, MedInsight. 8o. Congresso Htai – Rio de Janeiro, 2011.

42. Cost-effectiveness and budget impact analysis of Rivaroxaban in the prevention of thromboembolic events in patients performing hip and knee arthroplasty in comparison with no treatment under the Brazilian private health care system perspective. Alexandre Schiola, Bayer; Alessandra Pimentel Silva, Bayer; Natália Bolzachini Santoni, Bayer; Luciano Paladini, Evidências; Vanessa Teich, MedInsight; Camila Pepe, MedInsight; Monique Marinho, MedInsight. 8o. Congresso Htai – Rio de Janeiro, 2011.

43. Cost-effectiveness of Lapatinib combined with hormone therapy in patients with her2+/ hormone receptors positive (HR+) metastatic breast cancer (MBC) in Brazil. Camila Pepe, MedInsight; Talita Marinho, MedInsight; Márcio Machado, Glaxosmithkline; Vivian Blunk, Glaxosmithkline; Luciano Paladini, Evidências. 8o. Congresso Htai – Rio de Janeiro, 2011.

44. Resource use and associated costs for the treatment of heavy menstrual bleeding with levonorgestrel releasing intrauterine system (LNG-IUS) versus hysterectomy: the Brazilian public healthcare system (SUS) perspective. Luis Bahamondes, UNICAMP; Valéria Bahamondes, UNICAMP; Alexandre Schiola, Bayer; Alessandra Pimentel Da Silva, Bayer; Natália Bolzachini Santoni, Bayer; Mayra Moura, MedInsight; Jonas Salem, MedInsight;Luciana Clark, Evidências; Vanessa Teich, MedInsight. 8o. Congresso Htai – Rio de Janeiro, 2011.

45. Criteria for incorporation of new medicines to treat hematological cancer (HC) in the Brazilian public healthcare system (SUS): is there an informal cost- effectiveness (CE) threshold? Otávio Clark, Evidências; Vanessa Teich, MedInsight. 8o. Congresso Htai – Rio de Janeiro, 2011.

46. Evidence-based auditing of oncology treatments in a private healthcare system: a Brazilian experience. Patricia Medina, Evidências; Anna Alves, Evidências; Ana Castro, Evidências; Tobias Engel, Evidências; Bruna Pegoretti, Evidências; Otávio Clark, Evidências; Luciana Clark, Evidências; Adelissa Pizzol, Evidências. 8o. Congresso Htai – Rio de Janeiro, 2011.